全文获取类型
收费全文 | 268723篇 |
免费 | 38310篇 |
国内免费 | 2819篇 |
专业分类
耳鼻咽喉 | 6329篇 |
儿科学 | 8804篇 |
妇产科学 | 4375篇 |
基础医学 | 19214篇 |
口腔科学 | 3642篇 |
临床医学 | 38161篇 |
内科学 | 71630篇 |
皮肤病学 | 8833篇 |
神经病学 | 26195篇 |
特种医学 | 9992篇 |
外国民族医学 | 1篇 |
外科学 | 57467篇 |
综合类 | 1881篇 |
现状与发展 | 72篇 |
一般理论 | 156篇 |
预防医学 | 17407篇 |
眼科学 | 6551篇 |
药学 | 9544篇 |
1篇 | |
中国医学 | 284篇 |
肿瘤学 | 19313篇 |
出版年
2024年 | 736篇 |
2023年 | 5265篇 |
2022年 | 2188篇 |
2021年 | 5301篇 |
2020年 | 7271篇 |
2019年 | 4441篇 |
2018年 | 9913篇 |
2017年 | 9151篇 |
2016年 | 10486篇 |
2015年 | 10889篇 |
2014年 | 19026篇 |
2013年 | 20687篇 |
2012年 | 13661篇 |
2011年 | 14275篇 |
2010年 | 14979篇 |
2009年 | 18436篇 |
2008年 | 13548篇 |
2007年 | 12300篇 |
2006年 | 14313篇 |
2005年 | 11692篇 |
2004年 | 10517篇 |
2003年 | 8930篇 |
2002年 | 8757篇 |
2001年 | 4866篇 |
2000年 | 3811篇 |
1999年 | 4320篇 |
1998年 | 4970篇 |
1997年 | 4552篇 |
1996年 | 4211篇 |
1995年 | 4043篇 |
1994年 | 2682篇 |
1993年 | 2298篇 |
1992年 | 2007篇 |
1991年 | 1974篇 |
1990年 | 1568篇 |
1989年 | 1656篇 |
1988年 | 1505篇 |
1987年 | 1325篇 |
1986年 | 1282篇 |
1985年 | 1199篇 |
1984年 | 1101篇 |
1983年 | 1037篇 |
1982年 | 1192篇 |
1981年 | 1004篇 |
1980年 | 889篇 |
1979年 | 672篇 |
1978年 | 674篇 |
1977年 | 737篇 |
1976年 | 521篇 |
1975年 | 542篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
Matthew S Lewis Paul Maruff Brendan S Silbert Lis A Evered David A Scott 《Archives of clinical neuropsychology》2006,21(5):421-427
The reliable change index (RCI) expresses change relative to its associated error, and is useful in the identification of post-operative cognitive dysfunction (POCD). This paper examines four common RCIs that each account for error in different ways. Three rules incorporate a constant correction for practice effects and are contrasted with the standard RCI that had no correction for practice. These rules are applied to 160 patients undergoing coronary artery bypass graft (CABG) surgery who completed neuropsychological assessments preoperatively and 1 week post-operatively using error and reliability data from a comparable healthy non-surgical control group. The rules all identify POCD in a similar proportion of patients, but the use of the within subject standard deviation, expressing the effects of random error, as an error estimate is a theoretically appropriate denominator when a constant error correction, removing the effects of systematic error, is deducted from the numerator in a RCI. 相似文献
54.
55.
Henk R Franke F Froukje Snaaijer Paul W H Houben Marius J van der Mooren 《Gynecological endocrinology》2006,22(12):692-697
OBJECTIVE: To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women. METHODS: In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score). RESULTS: Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups. CONCLUSIONS: Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss. 相似文献
56.
57.
58.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
59.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
60.
PURPOSE: Concern over stigma as a consequence of genetic testing has grown in response to the recent increase in genetic research and testing resulting from the Human Genome Project. However, whether a genetic or hereditary basis necessarily confers a stigma to a condition remains unexamined. METHODS: We performed a qualitative interview study with 86 individuals with one of four conditions: deafness or hearing loss, breast cancer, sickle cell disease, and cystic fibrosis. The first two groups were divided approximately between people who ascribed their conditions to a genetic or hereditary cause and those who did not. RESULTS: Respondents interpreted genetic or hereditary causes and nongenetic causes in a variety of ways. Subjects with breast cancer reported the most consistently negative interpretation of genetic cause. This response concerned future ill health, not an enduring sense of stigma. Deaf and hard of hearing subjects provided the most consistently positive comments about a genetic or hereditary basis to their condition, casting familial hearing loss as a vital component of group and individual identity. Respondents with sickle cell disease and cystic fibrosis offered similar and positive interpretations of the genetic cause of their condition insofar as it meant their conditions were not contagious. CONCLUSIONS: Although some subjects report feeling stigmatized as a result of their condition, this stigmatization is not uniformly associated with the condition's cause, genetic or otherwise. Instead, stigma emerges from a variety of sources in the context of the lived experience of a particular condition. 相似文献